Phosphodiesterase inhibitors. Part 5: hybrid PDE3/4 inhibitors as dual bronchorelaxant/anti-inflammatory agents for inhaled administration
…, A Kojima, T Eiraku, K Iwase, T Kishi, A Ohinata…
Index: Ochiai, Koji; Takita, Satoshi; Kojima, Akihiko; Eiraku, Tomohiko; Iwase, Kazuhiko; Kishi, Tetsuya; Ohinata, Akira; Yageta, Yuichi; Yasue, Tokutaro; Adams, David R.; Kohno, Yasushi Bioorganic and Medicinal Chemistry Letters, 2013 , vol. 23, # 1 p. 375 - 381
Full Text: HTML
Citation Number: 20
Abstract
(−)-6-(7-Methoxy-2-(trifluoromethyl) pyrazolo [1, 5-a] pyridin-4-yl)-5-methyl-4, 5- dihydropyridazin-3 (2H)-one (KCA-1490) exhibits moderate dual PDE3/4-inhibitory activity and promises as a combined bronchodilatory/anti-inflammatory agent. N-alkylation of the pyridazinone ring markedly enhances potency against PDE4 but suppresses PDE3 inhibition. Addition of a 6-aryl-4, 5-dihydropyridazin-3 (2H)-one extension to the N-alkyl ...
Related Articles:
[Chan, Louis K. M.; Poole, Darren L.; Shen, Di; Healy, Mark P.; Donohoe, Timothy J. Angewandte Chemie - International Edition, 2014 , vol. 53, # 3 p. 761 - 765 Angew. Chem., 2014 , vol. 126, # 3 p. 908]
[Krishnamoorthy, Ravi; Lam, Sang Q.; Manley, Christopher M.; Herr, R. Jason Journal of Organic Chemistry, 2010 , vol. 75, # 4 p. 1251 - 1258]
Regulation of stress-induced cytokine production by pyridinylimidazoles; inhibition of CSBP kinase
[Bioorganic and Medicinal Chemistry, , vol. 5, # 1 p. 49 - 64]